<DOC>
	<DOC>NCT02612857</DOC>
	<brief_summary>The purpose of this study is to determine how safe and effective IMO-8400 is in adults with dermatomyositis.</brief_summary>
	<brief_title>Trial of IMO-8400 in Adult Patients With Dermatomyositis</brief_title>
	<detailed_description>This study will evaluate the safety and efficacy of IMO-8400 in adults with active dermatomyositis (DM).</detailed_description>
	<mesh_term>Dermatomyositis</mesh_term>
	<criteria>Has definite or probable DM based on the criteria of Bohan and Peter Has a Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)Activity score â‰¥15 Patients with muscle weakness are eligible; however having muscle weakness is not mandatory. Study participants must have a diagnostic evaluation for cancer if the diagnosis of DM was within 2 years prior to the Screening Visit Has ongoing severe dysphagia (e.g., requires a feeding tube) for the 3 months prior to Screening Has known hypersensitivity to any oligodeoxynucleotide Has a history of drug or alcohol abuse within one year of screening, or evidence of drug abuse by urine drug screening Has body weight &gt;140 kg Has a diagnosis of Juvenile DM, IBM, druginduced toxic myopathy, metabolic myopathy, dystrophy, cancerassociated DM, or connective tissue diseaseassociated DM (e.g., overlap syndrome) Has received one or more of following prohibited treatments within the interval noted prior to Screening (Visit 1): 1. Rituximab within 24 weeks (Note: patients who received rituximab are only eligible for inclusion if Bcell counts are confirmed to be within normal limits) 2. Intravenous corticosteroids within 12 weeks 3. Antimalarials (e.g., hydroxychloroquine) within 36 weeks 4. Topical corticosteroids (excluding scalp) within 2 weeks Has evidence of or has required treatment for cancer (except for treated, noninvasive carcinoma of the skin or cured cervical carcinomainsitu) within 5 years Has interstitial lung disease requiring the use of supplemental oxygen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>dermatomyositis</keyword>
	<keyword>IMO-8400</keyword>
	<keyword>Pioneer</keyword>
</DOC>